5/6
08:05 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $47.00 price target on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $47.00 price target on the stock.
5/6
08:05 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $31.00 price target on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $31.00 price target on the stock.
5/6
08:02 am
dyn
Rating for DYN
Low
Report
Rating for DYN
5/6
07:54 am
dyn
Rating for DYN
Low
Report
Rating for DYN
5/6
07:54 am
dyn
Rating for DYN
Low
Report
Rating for DYN
5/3
05:07 pm
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
4/30
07:15 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $40.00 price target on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $40.00 price target on the stock.
4/30
07:15 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $40.00 price target on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $40.00 price target on the stock.
4/30
05:16 am
dyn
Rating for DYN
Low
Report
Rating for DYN
4/30
05:16 am
dyn
Rating for DYN
Low
Report
Rating for DYN
3/26
10:44 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $47.00 price target on the stock.
Medium
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $47.00 price target on the stock.
3/26
10:06 am
dyn
Rating for DYN
Low
Report
Rating for DYN
3/26
10:06 am
dyn
Rating for DYN
Low
Report
Rating for DYN
3/8
03:55 am
dyn
Rating for DYN
Medium
Report
Rating for DYN
3/7
11:17 am
dyn
Rating for DYN
Low
Report
Rating for DYN
3/7
11:17 am
dyn
Rating for DYN
Low
Report
Rating for DYN
3/6
01:35 pm
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
3/6
10:22 am
dyn
Rating for DYN
Low
Report
Rating for DYN
3/5
08:14 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $47.00 price target on the stock, up previously from $44.00.
High
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $47.00 price target on the stock, up previously from $44.00.
3/5
07:51 am
dyn
Rating for DYN
Medium
Report
Rating for DYN
3/5
07:51 am
dyn
Rating for DYN
Medium
Report
Rating for DYN
2/20
07:17 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $36.00 price target on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $36.00 price target on the stock.
2/20
07:17 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $36.00 price target on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $36.00 price target on the stock.